



HAP Commercial Formulary - Medical Drugs Buy and Bill Update

Effective January 1, 2024, the drugs below will be available as buy and bill only.

| Label Name | |
|--------------------|--------------------|
| • ABILIFY MAINTENA | • HALDOL DECANOATE |
| • ARALAST | • INVEGA SUSTENNA |
| • BERINERT | • NEUPOGEN |
| • CINQAIR VIAL | • NIVESTYM |
| • CINRYZE | • PROLASTIN C |
| • CRYSVITA | • RELEUKO |
| • DDAVP | • SYNAGIS |
| • DESMOPRESSIN | • VELETRI VIAL |
| • DIGOXIN | • XOLAIR VIAL |
| • FASENRA | • ZARXIO |
| • GRANIX | • ZEMAIRA |

Buy-and-bill is a process for physician offices to acquire medications that providers can administer in the office. The “buy” part refers to providers who are responsible for ordering and purchasing the drug. The “bill” part refers to providers billing directly to third-party payers for reimbursement.

For the most current information, be sure to check the *Procedure Reference List* under *Quick Links* when you log in at **hap.org**.